These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 27732933

  • 1. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
    Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K.
    Oncotarget; 2016 Nov 29; 7(48):78605-78618. PubMed ID: 27732933
    [Abstract] [Full Text] [Related]

  • 2. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM.
    Oncotarget; 2016 Nov 29; 7(48):78896-78909. PubMed ID: 27806331
    [Abstract] [Full Text] [Related]

  • 3. CCR10 activation stimulates the invasion and migration of breast cancer cells through the ERK1/2/MMP-7 signaling pathway.
    Lin HY, Sun SM, Lu XF, Chen PY, Chen CF, Liang WQ, Peng CY.
    Int Immunopharmacol; 2017 Oct 29; 51():124-130. PubMed ID: 28830025
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manié S, Dumontet C.
    Clin Cancer Res; 2013 Jul 01; 19(13):3556-66. PubMed ID: 23674497
    [Abstract] [Full Text] [Related]

  • 5. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S, Theile D, Schäfer J, Seckinger A, Burhenne J, Weiss J.
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct 01; 389(10):1091-101. PubMed ID: 27422413
    [Abstract] [Full Text] [Related]

  • 6. CCR10 and CCL27 are overexpressed in cutaneous squamous cell carcinoma.
    Kai H, Kadono T, Kakinuma T, Tomita M, Ohmatsu H, Asano Y, Tada Y, Sugaya M, Sato S.
    Pathol Res Pract; 2011 Jan 15; 207(1):43-8. PubMed ID: 21144674
    [Abstract] [Full Text] [Related]

  • 7. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J, Park E, Jung CK, Kang SW, Kim BG, Jung Y, Kim TH, Lim JY, Lee SE, Min CK, Won KA.
    BMC Cancer; 2016 Mar 24; 16():247. PubMed ID: 27012957
    [Abstract] [Full Text] [Related]

  • 8. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
    Skorda A, Sklirou AD, Sakellaropoulos T, Gianniou DD, Kastritis E, Terpos E, Tsitsilonis OE, Florea BI, Overkleeft HS, Dimopoulos MA, Alexopoulos LG, Trougakos IP.
    J Cell Mol Med; 2019 Dec 24; 23(12):8010-8018. PubMed ID: 31568628
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
    Abdel Malek MA, Jagannathan S, Malek E, Sayed DM, Elgammal SA, Abd El-Azeem HG, Thabet NM, Driscoll JJ.
    Oncotarget; 2015 Feb 20; 6(5):3098-110. PubMed ID: 25605012
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
    Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ.
    Cancer Cell; 2016 May 09; 29(5):639-652. PubMed ID: 27132469
    [Abstract] [Full Text] [Related]

  • 18. Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma.
    Xu H, Han H, Song S, Yi N, Qian C, Qiu Y, Zhou W, Hong Y, Zhuang W, Li Z, Li B, Zhuang W.
    Clin Cancer Res; 2019 Mar 15; 25(6):1923-1935. PubMed ID: 30610101
    [Abstract] [Full Text] [Related]

  • 19. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E, Driscoll JJ.
    Oncotarget; 2016 Jun 21; 7(25):38523-38538. PubMed ID: 27229530
    [Abstract] [Full Text] [Related]

  • 20. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M.
    Rinsho Ketsueki; 2016 May 21; 57(5):537-45. PubMed ID: 27263777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.